ClinicalTrialsFinder
RecruitingNot ApplicableNCT06647368

Development of a Non-invasive Method for Quantifying Cerebral Glucose Metabolism for Studying the Effect of Glucagon in Humans

Investigating the Effect of Glucagon on Cognitive Function and Cerebral Glucose Metabolism in Humans: A Pilot study_A

Sponsor

Nicolai Jacob Wewer Albrechtsen

Enrollment

6 participants

Start Date

Oct 22, 2024

Study Type

INTERVENTIONAL

Conditions

Cerebral Glucose Metabolism

Summary

The aim of the study is to develop a non-invasive method for quantifying cerebral glucose metabolism by PET scans in humans. This method will be used in subsequent studies, where the effect of the pancreatic hormone glucagon on cerebral glucose metabolism will be studied. The golden standard for quantifying cerebral glucose metabolism by PET scans is based on arterial blood sampling, which complicates research setup. This study will investigate if image derived measurements instead of arterial blood samples can be used to quantify cerebral glucose metabolism. We will compare the calculations of cerebral glucose metabolism based on arterial blood samples and image derived measurements and hopefully these will correlate. Healthy participants will be included, and each participant will participate in one study day, which includes intravenous administration of radioactively labelled glucose (18-FDG), arterial blood sampling and PET scans.

Eligibility

Min Age: 25 YearsMax Age: 70 Years

Inclusion Criteria3

  • Capable of understanding the participant information and signing the consent form
  • Between 25 and 70 years of age
  • Body mass index \<= 25 kg/m\^2

Exclusion Criteria14

  • Enrolment in other research project that might interfere with the study
  • Diabetes diagnosis
  • Pregnancy or breastfeeding
  • Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol
  • Diagnosis of psychiatric disorders, dementias, or any other neurological disorders that in the opinion of the investigator precludes compliance with the study protocol, evaluation of the results or represents an unacceptable risk for the participants safety
  • Severe claustrophobia
  • Cardiac problems including any of the following:
  • Classified as being in New York Heart Association (NYHA) class III or IV
  • Angina pectoris (chest pain) within the last 6 months
  • Acute myocardial infarction (heart attack) within last 2 years
  • Inadequately treated blood pressure at screening defined as repeated resting blood pressure outside the range 90-150 mmHg for systolic and 50-100 mmHg for diastolic.
  • Active or recent malignant disease
  • Current or history of severe alcohol use or drug/chemical abuse as per investigator's judgement
  • Any chronic disorders or severe diseases which, in the opinion of the investigator, might jeopardise participant's safety or compliance with the protocol
Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPET with 18-FDG

The intervention is a 1,5 hour PET scan, which will be performed in three steps (heart scan, brain scan and heart scan) and administration of radioactively labelled glucose (18-FDG) in two doses.

Locations(1)

Department of Physiology and Nuclear Medicine, University of Copenhagen - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark

Copenhagen, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06647368